v3.24.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Revenue
For the years ended December 31, 2023, 2022 and 2021, revenue comprised the following:
Year Ended December 31,
(in thousands)202320222021
Prescription transactions revenue$550,738 $550,536 $593,359 
Subscription revenue94,410 96,167 59,925 
Pharma manufacturer solutions revenue (1)
85,065 99,425 73,348 
Other revenue20,052 20,426 18,792 
Total revenue$750,265 $766,554 $745,424 
_____________________________________________________
(1)Pharma manufacturer solutions revenue for the year ended December 31, 2023 included a $10.0 million contract termination payment to a pharma manufacturer solutions client in connection with our restructuring activities, which was recognized as a reduction of revenue. See "Note 17. Restructuring Plan" for additional information.